Gary Steventon's questions to Sanofi SA (SNY) leadership • Q2 2024
Question
Gary Steventon asked about the moving parts in the Vaccines business that support its mid-single-digit growth outlook despite a weaker forecast for flu. He also inquired about the performance trends of Dupixent's approved indications relative to its EUR 13 billion target for the year.
Answer
Thomas Triomphe, EVP of Vaccines, explained that the outlook is supported by Beyfortus achieving blockbuster status and slight growth in endemic products, which offsets the low single-digit decline expected for the overall flu market. Brian Foard, EVP and Head of Global Hub, Specialty Care GBU, stated that Dupixent's performance is strong and demand-driven across all approved indications and geographies, which supports the confidence in reaching the EUR 13 billion target.